Search This Blog

Thursday, October 20, 2016

FDA Approves Lilly's LARTRUVO™ (olaratumab) in Combination with Doxorubicin for Soft Tissue Sarcoma (NYSE:LLY)

FDA Approves Lilly's LARTRUVO™ (olaratumab) in Combination with Doxorubicin for Soft Tissue Sarcoma (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.